GigaMune is a therapeutics company developing a novel technology for in vivo, T cell targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) for serious diseases such as cancer and autoimmune diseases. Our initial goal is to challenge conventional ex vivo cell therapy manufacturing by reducing costs and improving outcomes. Our eventual goal is to deliver any gene to any cell in any tissue location at any time. See our high throughput immune screening technology highlighted in Nature Biotechnology (DOI: 10.1038/s41587-020-0438-y), and our petabase-scale protein search algorithm, published in Nature (DOI: 10.1038/s41586-021-04332-2).
| Website | http://www.gigamune.com |
| Employees | 10 (4 on RocketReach) |
| Founded | 2017 |
| Address | 953 Indiana St, San Francisco, California 94107, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology, Science and Engineering, Medical, Health Care |
| Keywords | T Cell Therapy, Immunotherapy, Gene Therapy, Cancer Treatment, Car T Cell Therapy, Oncology Therapeutics, Autoimmune Disease Treatment, Cell Therapy Research, Precision Medicine, Biopharmaceutical, Drug Development, Pharmaceutical Research, Novel Therapy, Therapeutics, Clinical Stage, Biotechnology |
| Competitors | Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, GSK, Bristol Myers Squibb, Amgen, Sandoz, Receptos, a wholly-owned subsidiary of Celgene +52 more (view full list) |
Looking for a particular GigaMune employee's phone or email?
Matthew Spindler is the VP for Research of GigaMune.
4 people are employed at GigaMune.
GigaMune is based in San Francisco, California.